The German Biotechnology Sector 2010

Unlike the majority of other industries, German biotechnology has actually grown during the crisis. In 2009, the number of employees exceeded the 30,000 mark for the first time. These are the central results of the company survey carried out at the beginning of 2010 by the information platform biotechnologie.de on behalf of the Federal Ministry of Education and Research (BMBF).

The German Biotechnology Sector

Unlike the majority of other industries, German biotechnology has actually grown during the crisis. In 2009, the number of employees exceeded the 30,000 mark for the first time. In terms of turnover, biotech companies managed to maintain their course, even at the height of the crisis.

As with the previous year, this figure stood at two billion euros. Moreover, investments in the future have not been scaled back. At one billion euros, research spending remained at the same level as the previous year. The effect of this was that the drug candidate pipeline continued to grow in 2009. Nevertheless, concerns remain about the difficult financial
environment. These are the central results of the company survey carried out at the beginning of 2010 by the information platform biotechnologie.de on behalf of the Federal Ministry of Education and Research (BMBF).

The data are in compliance with the guidelines laid out by the Organization for Economic Cooperation and Development (OECD; see pages 27 ff for methodology). According to the survey, at 531, the number of companies occupied primarily with biotechnology in 2009 is higher than the 2008 figure (501).

Accompanying this, the number of employees also increased to 14,950 (2008: 14,450). The significance of biotechnology in companies where it represents only one aspect of business activities rose even more strongly.

The number of employees in this biotech sector rose by more than 1,000 to 16,650 (2008: 15,520).........(계속)

☞ 자세한 내용은 첨부파일을 참고하시기 바랍니다.